‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure A. Lauschke, U.K.M. Teichgräber, U. Frei, K.-U. Eckardt Kidney International Volume 69, Issue 9, Pages 1669-1674 (May 2006) DOI: 10.1038/sj.ki.5000310 Copyright © 2006 International Society of Nephrology Terms and Conditions
Figure 1 Relationship between the baseline RI and serum creatinine in all patients. NE, norepinephrine. Kidney International 2006 69, 1669-1674DOI: (10.1038/sj.ki.5000310) Copyright © 2006 International Society of Nephrology Terms and Conditions
Figure 2 Correlation between the baseline RI and PI in all patients. Kidney International 2006 69, 1669-1674DOI: (10.1038/sj.ki.5000310) Copyright © 2006 International Society of Nephrology Terms and Conditions
Figure 3 Percentage change of RI compared to baseline value after first and second dopamine infusion. A close linear relationship between both values (r=0.74, P<0.0001) indicates high reproducibility of the effect of dopamine. Kidney International 2006 69, 1669-1674DOI: (10.1038/sj.ki.5000310) Copyright © 2006 International Society of Nephrology Terms and Conditions
Figure 4 Intraindividual comparison and mean±s.d. of RI values during placebo and dopamine infusion in patients with and without ARF. In patients without ARF dopamine reduced the RI significantly (P<0.01, Wilcoxon test), whereas there was a significant increase in patients with ARF (P<0.01). Kidney International 2006 69, 1669-1674DOI: (10.1038/sj.ki.5000310) Copyright © 2006 International Society of Nephrology Terms and Conditions
Figure 5 Effect of dopamine on RI values in patients with and without norepinephrine (NE) infusion. Kidney International 2006 69, 1669-1674DOI: (10.1038/sj.ki.5000310) Copyright © 2006 International Society of Nephrology Terms and Conditions
Figure 6 Effect of dopamine on RI values in patients below or above 55 years.* and ° indicate outliers. Kidney International 2006 69, 1669-1674DOI: (10.1038/sj.ki.5000310) Copyright © 2006 International Society of Nephrology Terms and Conditions
Figure 7 Schematic presentation of the study design. All patients received ‘low-dose’ dopamine or placebo for two periods of 1 h in alternating sequence and were randomly assigned to two groups receiving either dopamine or placebo first. Kidney International 2006 69, 1669-1674DOI: (10.1038/sj.ki.5000310) Copyright © 2006 International Society of Nephrology Terms and Conditions